Health Care·Biotechnology·$24.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $6.63 | N/A | +5.41% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $6.63 | N/A | +5.41% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to ongoing strategic initiatives. However, they did not provide specific revenue guidance.
We are pleased with our EPS performance this quarter.
While we did not provide revenue guidance, we remain focused on our strategic initiatives.
United Therapeutics reported a strong EPS performance, exceeding expectations, which contributed to a modest stock increase of 0.77%. The lack of revenue data and guidance suggests that investors may need to wait for more information in future reports. The positive EPS surprise indicates that the company is managing its costs effectively, but the absence of revenue details leaves some uncertainty.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
REVVITY INC
Apr 28, 2025